NCT06228963View on ClinicalTrials.gov

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2028

Conditions
MALT Lymphoma of StomachHelicobacter Pylori Infection
Interventions
DRUG

Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib

Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)

DRUG

Triple therapy for eradication of Helicobacter Pylori

Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER